To assist with the shared clinical decision-making around the option to vaccinate against meningococcal serogroup B disease and the timing of vaccination, CDC has provided some specific considerations about the disease and the vaccine that the patient and provider may weigh:
- Serious nature of invasive meningococcal serogroup B infection, with a high risk of death and permanent complications
- Low level of serogroup B disease in the United States, with an average of 34 cases each year among people age 16 through 23 years between 2015 and 2018, declining to 9 cases in 2020.
- Increased risk among college students, especially those who are freshmen, attending a 4-year university, living in on-campus housing, or participating in sorority and fraternity life
- Protection of MenB vaccine against most strains of meningococcal serogroup B bacteria
- Estimated relatively short duration of MenB vaccine protection, with antibody levels waning within 1–2 years of completing the primary series; however, if a booster is indicated (e.g., during an outbreak) antibody titers rise in one to two weeks after booster dose administration
- Evidence to date suggests no impact of MenB vaccine on meningococcal B carriage (may protect an individual from invasive disease but is unlikely to impact transmission of the bacteria to others)